Recombinant erythropoietin long-acting (Shandong Kexing Bioproducts)

长效重组促红细胞生成素

Report date: 2022/09/22 15:37:10

Base Information

Drug NameRecombinant erythropoietin long-acting (Shandong Kexing Bioproducts)

Drug Alias NamerhEPO (Shandong Kexing Bioproducts)Recombinant human erythropoietin (Shandong Kexing Bioproducts)Erythropoietin follow-on biologic (Shandong Kexing Bioproducts)YipudingEposino +[6]

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionErythropoietin receptor agonists

TargetsErythropoietin receptor

Therapy Area/IndicationsAnemia

Global Approved IndicationsAnemia

Approved Indications in ChinaAnemia

Original Approved Country/TerritoryMainland China

Original Approved Date2000/01/01

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesShandong Kexing Bio-Products Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShandong Kexing Bio-Products Co Ltd

Inactive CompaniesN/A

Active IndicationsAnemia

Inactive IndicationsN/A

Other Information

ATC CodeB03XA01